Decreasing acute toxicity and suppressing colorectal carcinoma using Sorafenib-loaded nanoparticles
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Decreasing acute toxicity and suppressing colorectal carcinoma using Sorafenib-loaded nanoparticles
Authors
Keywords
-
Journal
PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY
Volume -, Issue -, Pages 1-10
Publisher
Informa UK Limited
Online
2020-01-21
DOI
10.1080/10837450.2020.1718704
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A meta-analysis of efficacy and safety of sorafenib versus other targeted agents for metastatic renal cell carcinoma
- (2019) Hai-Tao Wang et al. MEDICINE
- Starch nanoparticles for delivery of the histone deacetylase inhibitor CG-1521 in breast cancer treatment
- (2019) Esma Alp et al. International Journal of Nanomedicine
- Dual-functionalized liposome by co-delivery of paclitaxel with sorafenib for synergistic antitumor efficacy and reversion of multidrug resistance
- (2019) Meng Lei et al. DRUG DELIVERY
- Drug Targeting Strategies Based on Charge Dependent Uptake of Nanoparticles into Cancer Cells
- (2019) Maryam Saadat et al. JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES
- Polymer-based nanoparticles for chemo/gene-therapy: Evaluation its therapeutic efficacy and toxicity against colorectal carcinoma
- (2019) Yan Chen et al. BIOMEDICINE & PHARMACOTHERAPY
- Inhibition of DDR1‐BCR signalling by nilotinib as a new therapeutic strategy for metastatic colorectal cancer
- (2018) Maya Jeitany et al. EMBO Molecular Medicine
- Adaptive immune cells are necessary for the enhanced therapeutic effect of sorafenib-loaded nanoparticles
- (2018) Zhi-Bin Zhao et al. Biomaterials Science
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs
- (2018) Sainan An et al. EBioMedicine
- MiR-30-5p suppresses cell chemoresistance and stemness in colorectal cancer through USP22/Wnt/β-catenin signaling axis
- (2018) Shixiong Jiang et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Thermo- and pH-responsive, Lipid-coated, Mesoporous Silica Nanoparticle-based Dual Drug Delivery System To Improve the Antitumor Effect of Hydrophobic Drugs
- (2018) Yi Feng et al. MOLECULAR PHARMACEUTICS
- Combined Tumor- and Neovascular-“Dual Targeting” Gene/Chemo-Therapy Suppresses Tumor Growth and Angiogenesis
- (2016) Bei Xu et al. ACS Applied Materials & Interfaces
- Matrix Metalloproteinase Responsive Nanoparticles for Synergistic Treatment of Colorectal Cancer via Simultaneous Anti-Angiogenesis and Chemotherapy
- (2016) Leilei Shi et al. BIOCONJUGATE CHEMISTRY
- Development and characterization of sorafenib-loaded PLGA nanoparticles for the systemic treatment of liver fibrosis
- (2016) Ts-Ting Lin et al. JOURNAL OF CONTROLLED RELEASE
- Improving Oral Bioavailability of Sorafenib by Optimizing the “Spring” and “Parachute” Based on Molecular Interaction Mechanisms
- (2016) Chengyu Liu et al. MOLECULAR PHARMACEUTICS
- FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation
- (2016) J Tong et al. ONCOGENE
- A Phase II Study of Sorafenib Combined With Cetuximab in EGFR-Expressing, KRAS-Mutated Metastatic Colorectal Cancer
- (2015) Khanh Do et al. Clinical Colorectal Cancer
- Comparison of a healthy miRNome with melanoma patient miRNomes: are microRNAs suitable serum biomarkers for cancer?
- (2015) Christiane Margue et al. Oncotarget
- Sorafenib: from literature to clinical practice
- (2013) V. Di Marco et al. ANNALS OF ONCOLOGY
- PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect
- (2010) Sarbari Acharya et al. ADVANCED DRUG DELIVERY REVIEWS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started